BBIO BridgeBio Pharma, Inc.
Price Chart
Executive Summary
A cluster of insider selling at BridgeBio Pharma (BBIO) occurred in the week following the Q1 2026 earnings release and the filing of a $500M at-the-market (ATM) equity offering. CFO Thomas Trimarchi sold $678K in open-market shares, and Director Randal Scott sold $413K, while CEO Neil Kumar exercised options and surrendered shares for tax withholding. The total open-market sales of $1.09M represent ~0.009% of BBIO's $12.8B market cap, which is trivial. The cluster is likely driven by routine post-earnings blackout window opening and tax-related transactions, not a coordinated bearish signal.
Key Financial Metrics
Actionable Insight
The insider selling is trivial in size and likely reflects post-earnings window opening and tax planning. The concurrent $500M ATM offering introduces potential dilution overhang, but the $500M buyback authorization partially offsets this. Monitor the pace of ATM usage and any insider purchases as a signal of management conviction.
Key Facts
- CFO Thomas Trimarchi sold 10,456 shares for $678K on May 18, 2026.
- Director Randal Scott sold 6,200 shares for $413K on May 15, 2026.
- CEO Neil Kumar exercised 33,544 options (non-cash) and surrendered 36,236 shares for tax withholding ($2.4M).
- Total open-market selling of $1.09M is only 0.009% of BBIO's $12.8B market cap.
- Q1 2026 revenue was $194.5M, including $180.6M in Attruby net product revenue.
- Company filed a $500M ATM equity offering on May 7, 2026, concurrent with a $500M share buyback authorization.
- Cash and marketable securities stood at $940.2M as of March 31, 2026.
Financial Impact
Open-market insider sales total $1.09M, which is immaterial relative to BBIO's $12.8B market cap.
Risk Factors
- The $500M ATM equity offering could dilute existing shareholders if fully utilized.
- Insider selling, while small, may continue if the stock appreciates further.
- Pipeline execution risk for BBP-418, encaleret, and infigratinib NDAs.
Market Snapshot
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-BBIO-1779222659731 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 19, 2026
1d ago
|
Insider Cluster
| — | awaiting T+5 | — | — |
|
May 12, 2026
8d ago
|
Press Release
| $65.95 $65.32 | ▼ −0.96% | ▼ −1.03% | $68.22 (+3.44%) |
|
May 11, 2026
9d ago
|
Press Release
| $64.68 $65.32 | ▲ +0.99% | ▲ +1.07% | $68.22 (+5.47%) |
|
May 8, 2026
12d ago
|
S-3ASR
| $67.39 $69.66 | ▲ +3.37% | ▲ +1.90% | $68.22 (+1.23%) |
|
May 7, 2026
13d ago
|
Press Release
| $67.39 $69.66 | ▲ +3.37% | ▲ +1.90% | $68.22 (+1.23%) |
|
May 6, 2026
14d ago
|
Press Release
| $68.09 $65.95 | ▼ −3.14% | ▼ −4.27% | $68.22 (+0.19%) |
|
May 5, 2026
15d ago
|
Press Release
| $68.78 $65.95 | ▼ −4.11% | ▼ −6.10% | $68.22 (−0.81%) |
|
Apr 24, 2026
26d ago
|
DEFA14A
| $74.52 $68.99 | ▼ −7.42% | ▼ −7.82% | $68.22 (−8.45%) |
|
Mar 11, 2026
10w ago
|
Press Release
| $71.39 $70.12 | ▼ −1.78% | ▲ +0.41% | $68.22 (−4.44%) |
|
Mar 10, 2026
10w ago
|
Insider Cluster
| $74.32 $70.94 | ▼ −4.55% | ▼ −3.64% | $68.22 (−8.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access